In connection with the Rights Issue, the Company has prepared a disclosure document in accordance with article 1.4 db Regulation (EU) 2017/1129 of the European Parliament and of Counsil of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation"). The disclosure document has been drafted in accordance with annex IX of the Prospectus Regulation.

Today, Peptonic announces that the Disclosure document has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and made available on the Company's website, www.peptonicmedical.se

To provide a more comprehensive basis for decision-making ahead of the forthcoming Rights Issue, the Company has also prepared an Investment Memorandum (the "Memorandum"). The Memorandum, containing complete terms and conditions, will be available on the Company's website, www.peptonicmedical.se and on Mangold Fondkommission AB's website, www.mangold.se. Information about the Rights Issue will be made available on the Company's website and on Mangold Fondkommission AB's website in connection with the start of the subscription period.

Preliminary timetable for the Rights Issue

• 9 January 2025: Record date for obtaining unit rights. Shareholders who were registered in the share register kept by Euroclear Sweden AB on this day, received unit rights for participation in the Rights Issue.
• 13 January - 27 January 2025: Subscription period for the Rights Issue
• 13 January - 27 January 2025: Trading with unit rights (UR) on Spotlight Stock Market
• 13 January - week 8 2025: Trading with paid subscribed units (BTU) on Spotlight Stock Market
• 29 January 2025: Estimated date for publication of the outcome in the Rights Issue

Advisers

Mangold Fondkommission AB is financial adviser to Peptonic in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is legal adviser to the Company in connection with the Rights Issue.

For more information contact:

Anna Linton, CEO Peptonic Medical AB

Email: anna.linton@peptonicmedical.se

Phone:  +46 70-244 92 07

About Peptonic Medical AB                                                                                                  

PEPTONIC medical AB (publ) is a pioneering Swedish medical device company, focused on the development and sale of clinically proven self-care treatments and self-diagnostic tests in the field of women's intimate health. The product portfolio is marketed under the brands VagiVital and Vernivia. The company aim to revolutionize intimate self-care by providing women a unique comprehensive solution to independently diagnose, treat, and prevent medical conditions in the intimate area. A key pillar of Peptonic's growth strategy is the geographic expansion of VagiVital and Vernivia in the U.S. and Europe. The company also seeks to continuously expand its product portfolio through acquisitions and in-house product development.

Peptonic Medical is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc, in the U.S. Founded in 2009, Peptonic Medical has been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.